Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases.

[1]  Kristen K. Reynolds,et al.  Clinical Utility and Economic Impact of CYP2D6 Genotyping. , 2016, Clinics in laboratory medicine.

[2]  Julie A. Johnson,et al.  A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication , 2015, PloS one.

[3]  T. Michiue,et al.  Postmortem analyses of drugs in pericardial fluid and bone marrow aspirate. , 2013, Journal of analytical toxicology.

[4]  Iain M McIntyre,et al.  Antemortem and postmortem methamphetamine blood concentrations: three case reports. , 2013, Journal of analytical toxicology.

[5]  M. Schwab,et al.  META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS , 2013, Clinical pharmacology and therapeutics.

[6]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[7]  R. de la Torre,et al.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? , 2012, Front. Gene..

[8]  A. Jones,et al.  Concentration ratios of methamphetamine to amphetamine in blood can help to distinguish use of methamphetamine from various mixtures of the two stimulants. , 2012, Journal of analytical toxicology.

[9]  Joseph McGraw,et al.  Cytochrome P450 variations in different ethnic populations , 2012, Expert opinion on drug metabolism & toxicology.

[10]  N. Volkow,et al.  Distribution and Pharmacokinetics of Methamphetamine in the Human Body: Clinical Implications , 2010, PloS one.

[11]  F. Vaida,et al.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings , 2010, Journal of the International Neuropsychological Society.

[12]  Yusuke Nakamura,et al.  Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays , 2010, Pharmacogenetics and genomics.

[13]  Masahiro Hiratsuka,et al.  Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.

[14]  M. Iyo,et al.  Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence , 2008, Neuroscience Letters.

[15]  A. Gaedigk,et al.  CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS , 2006, Drug Metabolism and Disposition.

[16]  A. Galli,et al.  Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. , 2003, European journal of pharmacology.

[17]  I. Cascorbi.  Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.

[18]  Mellar P. Davis,et al.  The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine , 2001, Supportive Care in Cancer.

[19]  K. Chiba,et al.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. , 2000, British journal of clinical pharmacology.

[20]  G. Tucker,et al.  Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[21]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  M. Baur,et al.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. , 1987, British journal of clinical pharmacology.

[23]  J. Caldwell,et al.  Metabolism of [14C]methamphetamine in man, the guinea pig and the rat , 1972 .

[24]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[25]  O. Drummer.  Drugs in Bone and Bone Marrow , 2008 .

[26]  A. M. Salazar,et al.  Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users. , 2007, Journal of analytical toxicology.

[27]  M. Kitada.  Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. , 2003, International journal of clinical pharmacology research.

[28]  F. Barnhart,et al.  Methamphetamine--a study of postmortem redistribution. , 1999, Journal of analytical toxicology.